{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:33:02Z","timestamp":1787668382366,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82003044"],"award-info":[{"award-number":["82003044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["80102022503"],"award-info":[{"award-number":["80102022503"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02867-0","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:34:48Z","timestamp":1781613288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Induction chemotherapy for locally advanced OPSCC: real-world evidence and HPV-dependent prognostic value of treatment response"],"prefix":"10.1186","volume":"21","author":[{"given":"Gulidanna","family":"Shayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"2867_CR1","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"J-P Machiels","year":"2020","unstructured":"Machiels J-P, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:1462\u201375.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2867_CR2","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","volume":"33","author":"ML Gillison","year":"2015","unstructured":"Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:3235\u201342.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2867_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.seminoncol.2004.09.011","volume":"31","author":"ML Gillison","year":"2004","unstructured":"Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31:744\u201354.","journal-title":"Semin Oncol"},{"key":"2867_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335.","journal-title":"N Engl J Med"},{"key":"2867_CR5","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","volume":"29","author":"AK Chaturvedi","year":"2011","unstructured":"Chaturvedi AK, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:4294\u2013301.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2867_CR6","unstructured":"National comprehensive cancer network. (Version 2.2025). NCCN clinical practice guidelines in oncology: Head and Neck Cancers. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf."},{"key":"2867_CR7","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695\u2013704.","journal-title":"N Engl J Med"},{"key":"2867_CR8","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","volume":"357","author":"MR Posner","year":"2007","unstructured":"Posner MR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705\u201315.","journal-title":"N Engl J Med"},{"key":"2867_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","volume":"14","author":"R Haddad","year":"2013","unstructured":"Haddad R, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257\u201364.","journal-title":"Lancet Oncol"},{"key":"2867_CR10","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","volume":"32","author":"EEW Cohen","year":"2014","unstructured":"Cohen EEW, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:2735\u201343.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2867_CR11","first-page":"164","volume":"73","author":"JJ Kang","year":"2023","unstructured":"Kang JJ, et al. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J Clin. 2023;73:164\u201397.","journal-title":"CA Cancer J Clin"},{"key":"2867_CR12","doi-asserted-by":"publisher","first-page":"110578","DOI":"10.1016\/j.radonc.2024.110578","volume":"201","author":"R Li","year":"2024","unstructured":"Li R, et al. p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy? Radiother Oncol. 2024;201:110578.","journal-title":"Radiother Oncol"},{"key":"2867_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijrobp.2023.07.037","volume":"118","author":"T Xu","year":"2024","unstructured":"Xu T, et al. Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01). Int J Radiat Oncol Biol Phys. 2024;118:169\u201378.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2867_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.5858\/arpa.2017-0286-CP","volume":"142","author":"JS Lewis","year":"2018","unstructured":"Lewis JS, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018;142:559\u201397.","journal-title":"Arch Pathol Lab Med"},{"key":"2867_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas B, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2021;156:281\u201393.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2867_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oraloncology.2015.12.008","volume":"54","author":"DJ Sher","year":"2016","unstructured":"Sher DJ, et al. Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis. Oral Oncol. 2016;54:58\u201367.","journal-title":"Oral Oncol"},{"key":"2867_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/COC.0b013e31827a7cff","volume":"37","author":"JJ Caudell","year":"2014","unstructured":"Caudell JJ, et al. Induction docetaxel, Cisplatin, and 5-Fluorouracil precludes definitive chemoradiotherapy in a substantial proportion of patients with head and neck cancer in a low socioeconomic status population. Am J Clin Oncol. 2014;37:332\u20136.","journal-title":"Am J Clin Oncol"},{"key":"2867_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00066-013-0509-9","volume":"190","author":"P Balermpas","year":"2014","unstructured":"Balermpas P, et al. Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2014;190:256\u201362.","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"key":"2867_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.oraloncology.2018.01.031","volume":"78","author":"O Bhattasali","year":"2018","unstructured":"Bhattasali O, et al. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease. Oral Oncol. 2018;78:151\u20135.","journal-title":"Oral Oncol"},{"key":"2867_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2025.0848","author":"SH Huang","year":"2025","unstructured":"Huang SH, et al. A Proposal for HPV-Associated Oropharyngeal Carcinoma in the Ninth Edition Clinical TNM Classification. JAMA Otolaryngol Neck Surg. 2025. https:\/\/doi.org\/10.1001\/jamaoto.2025.0848.","journal-title":"JAMA Otolaryngol Neck Surg"},{"key":"2867_CR21","doi-asserted-by":"publisher","unstructured":"Fan C, et al. Imaging Extranodal Extension (iENE) Predicts higher rates of distant recurrence for human papillomavirus-positive oropharyngeal cancer. Int J Radiat Oncol. 2025;S0360301625003104. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.048.","DOI":"10.1016\/j.ijrobp.2025.03.048"},{"key":"2867_CR22","doi-asserted-by":"publisher","unstructured":"Mehanna H, et al. Accuracy and prognosis of extranodal extension on radiologic imaging in human papillomavirus-mediated oropharyngeal cancer: a head and neck cancer international group (HNCIG) real-world study. Int J Radiat Oncol. 2025;S0360301625003700. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.04.003.","DOI":"10.1016\/j.ijrobp.2025.04.003"},{"key":"2867_CR23","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.20.03128","volume":"39","author":"SS Yom","year":"2021","unstructured":"Yom SS, et al. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). J Clin Oncol Off J Am Soc Clin Oncol. 2021;39:956\u201365.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2867_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","volume":"10","author":"AJ Rosenberg","year":"2024","unstructured":"Rosenberg AJ, et al. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024;10:923\u201331.","journal-title":"JAMA Oncol"},{"key":"2867_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","volume":"24","author":"H Mehanna","year":"2023","unstructured":"Mehanna H, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol. 2023;24:239\u201351.","journal-title":"Lancet Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02867-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:03:22Z","timestamp":1787666602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02867-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2867"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02867-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Eye & ENT Hospital of Fudan University (Approval No. 2022086). Given the retrospective nature of the study, the Ethics Committee granted a waiver of informed consent for participant enrollment. The study was conducted in accordance with the principles of the Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No identifiable personal information is included in this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}